696 results on '"Correa-Rotter, Ricardo"'
Search Results
2. First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting
3. Mind the gap in kidney care: translating what we know into what we do
4. Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex
5. New and emerging therapies for diabetic kidney disease
6. Long-term effects of hypercalcemia in kidney transplant recipients with persistent hyperparathyroidism
7. Dietary inflammatory index and lower glomerular filtration rate in Mexican adults
8. Projecting the clinical burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study
9. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
10. Association between soft drinks intake and low glomerular filtration rate in Mexican adults: Results from RenMex
11. Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria
12. Representation of Low- and Middle-Income Countries in CKD Drug Trials: A Systematic Review
13. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis
14. Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials
15. Validation of an equation for free calcium estimation: accuracy improves after adjustment for phosphate and CO2
16. How to Prepare a Chronic Kidney Disease Patient for Dialysis
17. Mind the Gap in Kidney Care: Translating What We Know into What We Do
18. The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis
19. #294 Pragmatic literature reviews to populate a patient-level model to project the future clinical burden of CKD in low-and middle-income countries
20. #255 PaCE CKD: the impact of caregiving on health states and work productivity in chronic kidney disease: results from an international survey
21. #254 PaCE CKD: examining health status and financial burden in patients with chronic kidney disease: assessing the non-clinical burden of disease
22. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
23. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure
24. Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
25. The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
26. Mind the Gap in Kidney Care: Translating What We Know Into What We Do.
27. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
28. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
29. WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
30. WCN24-1464 MEASUREMENT OF CEREBRAL BLOOD FLOW USING TRANSCRANIAL DOPPLER ULTRASOUND: COMPARISON OF TWO POPULATIONS OF PATIENTS IN CHRONIC HEMODIALYSIS
31. WCN24-890 INSIDE CKD - PRAGMATIC LITERATURE REVIEWS TO POPULATE A PATIENT-LEVEL MODEL TO PROJECT THE FUTURE CLINICAL BURDEN OF CKD IN FOUR LOW- AND MIDDLE INCOME COUNTRIES
32. WCN24-1229 EFFECTS OF TREATMENT AND CLINICAL EVENTS ON QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A PRESPECIFIED ANALYSIS OF THE DAPA-CKD TRIAL
33. Frequency of Intradialytic Hypotension Events Do Not Increase with Oral Nutritional Supplementation during Hemodialysis Treatment: A Randomized Controlled Trial
34. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
35. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
36. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
37. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
38. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
39. Ambient heat exposure and kidney function in patients with chronic kidney disease:a post-hoc analysis of the DAPA-CKD trial
40. Dapagliflozin in chronic kidney disease:cost-effectiveness beyond the DAPA-CKD trial
41. Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria
42. Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease across the Spectrum of Frailty
43. 423.9: The First 52 Global Kidney Exchange Transplants: Overcoming Multiple Barriers to Transplantation
44. Correction of anemia by dapagliflozin in patients with type 2 diabetes
45. Prevalence of thyroid dysfunction in healthy adults according to the estimated iodine intake in 24-hour urine samples: The SALMEX cohort
46. Conservative and Palliative Care in Old Age Individuals with End-Stage Renal Disease
47. Global Disparities in Chronic Kidney Disease Clinical Trials: A Systematic Review
48. Advances in hemodialysis in the last decade in Latin America
49. Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex
50. Mesoamerican Nephropathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.